Malin Corporation plc is a publicly listed investment company focused on the life sciences sector. The company primarily invests in innovative companies within oncology, immunology, and genetic diseases, aiming to support the development of transformative healthcare technologies. Malin provides long-term capital and strategic support to its investee companies, helping them to achieve their full value potential. Malin Corporation is headquartered in Dublin, Ireland, and its shares are listed on the Euronext Dublin.

Malin 

Malin  (MLC) H1 2025 Summary | Quartr

Google Play

App Store

App links

Article Categories

Prefooter USP - CTA App

Dig deeper into the Visa Inc fundamentals on Quartr.

Features CTA

Product

Use cases

Discover

Resources

Company

email

Features

Platforms

Featured article

Pricing

Contact sales

Simple CTA

events-root

Malin Corporation plc

Intrinsic equity value per share increased to €9.24, with major leadership changes and capital return.

H2 2025

Cash surges to €62.9m post-CG Oncology sale; €45m capital return planned for shareholders.

H1 2024

Major divestments drove a €150m capital return and record cash reserves for Malin in 2024.

H2 2024

### Executive summary
- Estimated intrinsic equity value was €41.3 million as of 30 June 2025, reflecting the fair value of investee companies and cash.
- Intrinsic equity value per share was €9.52 at 30 June 2025.

### Financial highlights
- Cash position stood at €13.7 million as of 30 June 2025.
- By 25 August 2025, estimated intrinsic equity value slightly decreased to €41.0 million.
- Cash balance as of 25 August 2025 was €13.4 million.
- Intrinsic equity value per share was €9.45 as of 25 August 2025.

H1 2025 earnings summary

H1 2025

Malin (MLC) H1 2025 earnings summary

H1 2025 earnings summary

Executive summary

Financial highlights

Latest events from Malin